Royalty Pharma lifts 2026 outlook amid strong cash flows

Royalty Pharma PLC ((RPRX)) has held its Q2 earnings call. Read on for the main highlights of the call.

Royalty Pharma’s latest earnings call struck an upbeat tone, as management highlighted robust double‑digit growth in recurring cash flows, a raised full‑year outlook and an upgraded credit rating. While acknowledging product‑specific headwinds, lower milestone receipts and regulatory uncertainty, executives stressed that strong cash generation and disciplined capital deployment position the company well for continued growth.

Double‑digit recurring cash flow growth

Royalty receipts climbed 14% year over year in the second quarter of 2026, underscoring the strength of the company’s recurring cash engine. Total portfolio receipts reached $773 million, up 6% and slightly ahead of expectations, reflecting broad‑based performance across key royalty assets.

Raised full‑year 2026 guidance

Management raised its 2026 portfolio receipts guidance to a range of $3.4 billion to $3.5 billion, up from $3.325 billion to $3.45 billion. The company now expects royalty receipts to grow about 7% to 10% this year, compared with a prior growth outlook of 4% to 8%.

Strong returns on capital and equity

Royalty Pharma underscored the attractiveness of its business model with a 14.2% return on invested capital over the past year. Return on invested equity came in even stronger at 20.1%, signaling efficient deployment of capital into high‑return royalty streams.

Material capital deployment and deal flow

Year to date, the company has deployed $1.1 billion on royalty acquisitions, backing deals with a combined announced value of $1.7 billion. Overall capital deployment reached $877 million in the first half of 2026, highlighting an active pipeline of opportunities and continued deal execution.

Strategic cliramitug acquisition

A centerpiece of recent activity is the purchase of a portion of Neurimmune’s royalty on AstraZeneca’s cliramitug for up to $425 million. With AstraZeneca projecting peak sales between $3 billion and $5 billion, Royalty Pharma expects peak royalties of roughly $110 million to $190 million and targets an internal rate of return in the mid‑teens.

Expanded and de‑risked development pipeline

Since its IPO, Royalty Pharma has expanded its development‑stage portfolio from three programs to nineteen, a sixfold increase. The late‑stage pipeline now carries an estimated $2 billion in peak potential royalties, backed by a cited 90% historical success rate for advancing development‑stage investments to approval.

Strong cash generation and balance sheet

Portfolio cash flow, defined as adjusted EBITDA less net interest, reached $736 million in the quarter with about 95% cash conversion. The company ended the period with $812 million in cash and equivalents, $9.2 billion in investment‑grade debt and leverage of roughly 2.8 times total debt to adjusted EBITDA.

Meaningful shareholder returns

Shareholders shared directly in the company’s cash strength, with about $370 million returned via dividends and buybacks in the first half. Royalty Pharma repurchased roughly 5 million shares in the quarter, trimming the weighted average share count by around 1% and returning nearly a quarter of portfolio cash flow year to date.

Decline in milestones and contractual receipts

One area of softness is milestones and other contractual receipts, which declined sharply from the prior year due to a one‑time payment in that period. Management now expects these receipts to fall from $128 million in 2025 to about $60 million in 2026, resetting expectations for this more volatile revenue line.

Product‑specific and market headwinds

The company’s guidance factors in several looming pressures, including the loss of exclusivity for Promacta and the U.S. launch of a biosimilar to Tysabri. Management also acknowledged potential revenue effects from the Inflation Reduction Act, signaling that these headwinds are incorporated into current forecasts.

Reliance on future pivotal outcomes

Royalty Pharma’s newer bets, including cliramitug, hinge on pivotal trial success, with a fully enrolled Phase III outcomes study expected to read out in 2028. While early biomarker data have been encouraging, the company stressed that commercial upside and targeted returns depend on positive late‑stage results.

Seasonality and higher operating costs

Operating and professional expenses were 4.8% of portfolio receipts in the second quarter, but full‑year guidance calls for 5.5% to 6.5%. That implies higher spending in the back half of the year, reflecting seasonal factors and integration‑related costs as the company digests recent deals.

Moderate leverage and debt profile

Royalty Pharma’s capital structure remains balanced, with investment‑grade debt of $9.2 billion and net leverage of about 2.6 times adjusted EBITDA. Management emphasized the importance of continued strong cash generation and disciplined capital allocation to maintain flexibility at these leverage levels.

China regulatory and geopolitical risks

The company is in the early stages of expanding into China, a market management describes as promising but complex. Executives highlighted potential risks from evolving U.S. legislative proposals and broader policy uncertainty, though they believe many existing royalty structures should prove resilient.

Guidance and outlook

Looking ahead, the upgraded 2026 guidance assumes royalty‑receipt growth of 7% to 10% and total portfolio receipts of $3.4 billion to $3.5 billion, even as milestones ease to about $60 million. Operating and professional costs are expected at 5.5% to 6.5% of receipts, interest paid around $350 million to $360 million, and the outlook excludes any upside from future royalty acquisitions.

Royalty Pharma’s earnings call painted the picture of a company leaning into growth while keeping a firm grip on risk, balancing robust recurring cash flows with active capital deployment and prudent leverage. For investors, the upgraded guidance, expanding pipeline and ongoing shareholder returns stand out as key positives, even as product headwinds, lower milestones and regulatory uncertainty temper the near‑term narrative.